Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow

Buschhaus, Johanna M.; Humphries, Brock A.; Eckley, Samantha S.; Robison, Tanner H.; Cutter, Alyssa C.; Rajendran, Shrila; Haley, Henry; Bevoor, Avinash S.; Luker, Gary D.

doi:10.1038/s41388-020-01391-z

Cited by 26 publications

(21 citation statements)

References 64 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this process, stromal cells produce energy-rich metabolites such as lactate through enhanced aerobic glycolysis, and cancer cells can convert these metabolites into pyruvate, providing fuel for the TCA cycle [ 47 ]. For example, disseminated breast tumor cells exhibit increased OXPHOS and increased fluorescence lifetimes compared to co-culture bone marrow stromal cells in the bone marrow niche [ 48 ]. However, not all tumor-stroma cell interactions conform to the reverse Warburg effect.…”

Section: Flim Combined With Nad(p)h For Cancer Metabolism Monitoringmentioning

confidence: 99%

FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring

et al. 2021

View full text Add to dashboard Cite

Fluorescence lifetime imaging microscopy (FLIM) has been rapidly developed over the past 30 years and widely applied in biomedical engineering. Recent progress in fluorophore-dyed probe design has widened the application prospects of fluorescence. Because fluorescence lifetime is sensitive to microenvironments and molecule alterations, FLIM is promising for the detection of pathological conditions. Current cancer-related FLIM applications can be divided into three main categories: (i) FLIM with autofluorescence molecules in or out of a cell, especially with reduced form of nicotinamide adenine dinucleotide, and flavin adenine dinucleotide for cellular metabolism research; (ii) FLIM with Förster resonance energy transfer for monitoring protein interactions; and (iii) FLIM with fluorophore-dyed probes for specific aberration detection. Advancements in nanomaterial production and efficient calculation systems, as well as novel cancer biomarker discoveries, have promoted FLIM optimization, offering more opportunities for medical research and applications to cancer diagnosis and treatment monitoring. This review summarizes cutting-edge researches from 2015 to 2020 on cancer-related FLIM applications and the potential of FLIM for future cancer diagnosis methods and anti-cancer therapy development. We also highlight current challenges and provide perspectives for further investigation.

show abstract

Section: Flim Combined With Nad(p)h For Cancer Metabolism Monitoringmentioning

confidence: 99%

FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Activation of AKT was shown to be high in breast cancer cells colonizing the bone marrow or when co-cultured with bone marrow stromal cells. Moreover, the inhibition of AKT by application of MK2206 decreases the proliferation of breast cancer cells in this co-culture in vitro [ 48 ]. Additionally, osteocyte-derived conditioned medium and the most abundant protein in bone, collagen I, increases the proliferation of breast cancer cells accompanied by elevated pAKT levels [ 49 ].…”

Section: Breast Cancermentioning

confidence: 99%

AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review

Hinz

Jücker

2021

Cancers

View full text Add to dashboard Cite

Solid tumors, such as breast cancer and prostate cancer, often form bone metastases in the course of the disease. Patients with bone metastases frequently develop complications, such as pathological fractures or hypercalcemia and exhibit a reduced life expectancy. Thus, it is of vital importance to improve the treatment of bone metastases. A possible approach is to target signaling pathways, such as the PI3K/AKT pathway, which is frequently dysregulated in solid tumors. Therefore, we sought to review the role of the serine/threonine kinase AKT in bone metastasis. In general, activation of AKT signaling was shown to be associated with the formation of bone metastases from solid tumors. More precisely, AKT gets activated in tumor cells by a plethora of bone-derived growth factors and cytokines. Subsequently, AKT promotes the bone-metastatic capacities of tumor cells through distinct signaling pathways and secretion of bone cell-stimulating factors. Within the crosstalk between tumor and bone cells, also known as the vicious cycle, the stimulation of osteoblasts and osteoclasts also causes activation of AKT in these cells. As a consequence, bone metastasis is reduced after experimental inhibition of AKT. In summary, AKT signaling could be a promising therapeutical approach for patients with bone metastases of solid tumors.

show abstract

“…Fortunately, the four basic practices noted above to reduce the risk of Mycoplasma infection also reduce the risk of cell line cross-contamination. Regular authentication solves one other common and related problem, knowing that the cell line being used is not an entirely different cell line [64] .…”

Section: Basic Issues In Reproducibility and Experimental Design For In Vitro Studiesmentioning

confidence: 99%

“…Most cell culture studies are done with cells growing on a 2D plastic surface, an approach that has proven useful for many types of studies for several decades. For some studies, a 3D culture matrix can offer a more physiologically relevant experimental context [ 48 , 65 ] . For example, 3D matrices can be prepared from ER+, human breast cancer-associated fibroblasts, or normal breast tissue (often obtained from reduction mammoplasties).…”

Section: Cell Lines As Models Of Er+ Breast Cancermentioning

confidence: 99%

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

Clarke

Jones

Sevigny

et al. 2021

CDR

View full text Add to dashboard Cite

Breast cancers characterized by expression of estrogen receptor-alpha (ER; ESR1) represent approximately 70% of all new cases and comprise the largest molecular subtype of this disease. Despite this high prevalence, the number of adequate experimental models of ER+ breast cancer is relatively limited. Nonetheless, these models have proved very useful in advancing understanding of how cells respond to and resist endocrine therapies, and how the ER acts as a transcription factor to regulate cell fate signaling. We discuss the primary experimental models of ER+ breast cancer including 2D and 3D cultures of established cell lines, cell line-and patient-derived xenografts, and chemically induced rodent models, with a consideration of their respective general strengths and limitations. What can and cannot be learned easily from these models is also discussed, and some observations on how these models may be used more effectively are provided. Overall, despite their limitations, the panel of models currently available has enabled major advances in the field, and these models remain central to the ability to study mechanisms of therapy action and resistance and for hypothesis testing that would otherwise be intractable or unethical in human subjects.

show abstract

Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow

Cited by 26 publications

References 64 publications

FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring

FLIM as a Promising Tool for Cancer Diagnosis and Treatment Monitoring

AKT in Bone Metastasis of Solid Tumors: A Comprehensive Review

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

Contact Info

Product

Resources

About